GILD

SEC source: 0001127602-22-011957 · form4.xml · nonDerivative · entry 1

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,353

F1 · shares: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Gilead Sciences, Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of August 16, 2021 through February 15, 2022. This transaction is exempt under Rule 16b-3(c).

F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on February 15, 2022.

SEC source: 0001127602-22-004516 · form4.xml · nonDerivative · entry 1

Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,576

F1 · kind: The sale transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan.

SEC source: 0001127602-22-003845 · form4.xml · derivative · entry 3

Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,043

Underlying: Common Stock · 1,864 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F2 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested.

F2 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested.

SEC source: 0001127602-22-003845 · form4.xml · nonDerivative · entry 2

Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,219

SEC source: 0001127602-22-003845 · form4.xml · nonDerivative · entry 1

Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,739

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

SEC source: 0001127602-22-003846 · form4.xml · derivative · entry 3

Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,024

Underlying: Common Stock · 2,727 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F2 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested.

F2 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested.

SEC source: 0001127602-22-003846 · form4.xml · nonDerivative · entry 2

Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,267

SEC source: 0001127602-22-003846 · form4.xml · nonDerivative · entry 1

Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,303

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

SEC source: 0001127602-22-003847 · form4.xml · derivative · entry 3

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,560

Underlying: Common Stock · 1,817 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F2 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested.

F2 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested.

SEC source: 0001127602-22-003847 · form4.xml · nonDerivative · entry 2

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,706

SEC source: 0001127602-22-003847 · form4.xml · nonDerivative · entry 1

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,473

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

SEC source: 0001127602-22-003048 · form4.xml · nonDerivative · entry 1

Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,576

F1 · kind: The sale transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan dated May 28, 2021.

F2 · price: Sale prices reported for the transaction reported here range from $68.34 to $68.76. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.

SEC source: 0001127602-22-002462 · form4.xml · nonDerivative · entry 3

Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,637

SEC source: 0001127602-22-002462 · form4.xml · nonDerivative · entry 2

Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,318

F2 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share award made to the Reporting Person on February 6, 2019. Such tranches of shares were subject to performance-vesting and service-vesting requirements and became issuable on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors.

SEC source: 0001127602-22-002462 · form4.xml · nonDerivative · entry 1

Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,576

F1 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on March 10, 2020, and March 10, 2021. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until the requisite continuing service requirements are also met.

SEC source: 0001127602-22-002463 · form4.xml · nonDerivative · entry 3

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,656

SEC source: 0001127602-22-002463 · form4.xml · nonDerivative · entry 2

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,272

F2 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share award made to the Reporting Person on February 6, 2019. Such tranches of shares were subject to performance-vesting and service-vesting requirements and became issuable on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors.

SEC source: 0001127602-22-002463 · form4.xml · nonDerivative · entry 1

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,116

F1 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on March 10, 2020, and March 10, 2021. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until the requisite continuing service requirements are also met.

SEC source: 0001127602-22-002464 · form4.xml · nonDerivative · entry 3

Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,875

SEC source: 0001127602-22-002464 · form4.xml · nonDerivative · entry 2

Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,269

F2 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share award made to the Reporting Person on February 6, 2019. Such tranches of shares were subject to performance-vesting and service-vesting requirements and became issuable on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors.

SEC source: 0001127602-22-002464 · form4.xml · nonDerivative · entry 1

Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,112

F1 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on March 10, 2020, and March 10, 2021. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until the requisite continuing service requirements are also met.

SEC source: 0001127602-22-002465 · form4.xml · nonDerivative · entry 1

Parsey Merdad · CIK 0001792150 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,158

F1 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on March 10, 2020, and March 10, 2021. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until the requisite continuing service requirements are also met.

SEC source: 0001127602-22-002466 · form4.xml · nonDerivative · entry 3

O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 205,354

SEC source: 0001127602-22-002466 · form4.xml · nonDerivative · entry 2

O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 239,187

F2 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share award made to the Reporting Person on February 6, 2019. Such tranches of shares were subject to performance-vesting and service-vesting requirements and became issuable on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors.

SEC source: 0001127602-22-002466 · form4.xml · nonDerivative · entry 1

O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 156,517

F1 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on March 10, 2020, and March 10, 2021. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until the requisite continuing service requirements are also met.

SEC source: 0001127602-22-002467 · form4.xml · nonDerivative · entry 1

Mercier Johanna · CIK 0001782135 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,778

F1 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on March 10, 2020, and March 10, 2021. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until the requisite continuing service requirements are also met.

SEC source: 0001127602-22-000170 · form4.xml · derivative · entry 1

Lofton Kevin E · CIK 0001468818 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,970.7278

Underlying: Common Stock · 28.476 shares

Expires not disclosed

F1 · security: Each share of phantom stock is the economic equivalent of one share of Gilead common stock.

F2 · shares: Phantom shares accrued under dividend equivalent rights, which are settled in shares and distributed with the phantom stock units to which they relate.

F3 · derivative.exercise_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person.

F3 · derivative.expiration_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person.

SEC source: 0001127602-21-030577 · form4.xml · derivative · entry 2

Bluestone Jeffrey · CIK 0001771814 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,223

Underlying: Common Stock · 1,041 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F2 · derivative.exercise_date: 100% of the restricted stock units vested on December 8, 2021.

F2 · derivative.expiration_date: 100% of the restricted stock units vested on December 8, 2021.

SEC source: 0001127602-21-030577 · form4.xml · nonDerivative · entry 1

Bluestone Jeffrey · CIK 0001771814 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,041

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

SEC source: 0001127602-21-029039 · form4.xml · derivative · entry 3

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,377

Underlying: Common Stock · 1,913 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock.

F2 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested.

F2 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested.

SEC source: 0001127602-21-029039 · form4.xml · nonDerivative · entry 2

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,015

SEC source: 0001127602-21-029039 · form4.xml · nonDerivative · entry 1

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,885

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock.

SEC source: 0001127602-21-029042 · form4.xml · derivative · entry 3

Parsey Merdad · CIK 0001792150 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,089

Underlying: Common Stock · 5,100 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F2 · derivative.exercise_date: The restricted stock units have a three year vesting schedule. 33.33% will vest on each yearly anniversary of the date of grant until fully vested.

F2 · derivative.expiration_date: The restricted stock units have a three year vesting schedule. 33.33% will vest on each yearly anniversary of the date of grant until fully vested.

SEC source: 0001127602-21-029042 · form4.xml · nonDerivative · entry 2

Parsey Merdad · CIK 0001792150 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,860

SEC source: 0001127602-21-029042 · form4.xml · nonDerivative · entry 1

Parsey Merdad · CIK 0001792150 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,180

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

SEC source: 0001127602-21-027629 · form4.xml · derivative · entry 2

WELTERS ANTHONY · CIK 0001213307 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,223

Underlying: Common Stock · 1,368 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F2 · derivative.exercise_date: 100% of the restricted stock units vested on October 22, 2021.

F2 · derivative.expiration_date: 100% of the restricted stock units vested on October 22, 2021.

SEC source: 0001127602-21-027629 · form4.xml · nonDerivative · entry 1

WELTERS ANTHONY · CIK 0001213307 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,368

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

SEC source: 0001127602-21-026321 · form4.xml · derivative · entry 1

Lofton Kevin E · CIK 0001468818 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,942.2518

Underlying: Common Stock · 29.1556 shares

Expires not disclosed

F1 · security: Each share of phantom stock is the economic equivalent of one share of Gilead common stock.

F2 · shares: Phantom shares accrued under dividend equivalent rights, which are settled in shares and distributed with the phantom stock units to which they relate.

F3 · derivative.exercise_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person.

F3 · derivative.expiration_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person.

SEC source: 0001127602-21-023999 · form4.xml · derivative · entry 5

Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,829 shares

Expires 2027-02-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001127602-21-023999 · form4.xml · derivative · entry 4

Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,869

Underlying: Common Stock · 9,781 shares

Expires 2029-02-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001127602-21-023999 · form4.xml · nonDerivative · entry 3

Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,398

SEC source: 0001127602-21-023999 · form4.xml · nonDerivative · entry 2

Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,008

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-21-023999 · form4.xml · nonDerivative · entry 1

Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,179

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-21-024261 · form4.xml · nonDerivative · entry 1

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,972

F1 · shares: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Gilead Sciences, Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of February 16, 2021 through August 15, 2021. This transaction is exempt under Rule 16b-3(c).

F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on February 16, 2021.

SEC source: 0001127602-21-024264 · form4.xml · nonDerivative · entry 1

Parsey Merdad · CIK 0001792150 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,080

F1 · shares: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Gilead Sciences, Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of February 16, 2021 through August 15, 2021. This transaction is exempt under Rule 16b-3(c).

F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on February 16, 2021.

SEC source: 0001127602-21-024266 · form4.xml · nonDerivative · entry 1

Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,198

F1 · shares: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Gilead Sciences, Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of February 16, 2021 through August 15, 2021. This transaction is exempt under Rule 16b-3(c).

F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on February 16, 2021.

SEC source: 0001127602-21-023570 · form4.xml · derivative · entry 3

Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,907

Underlying: Common Stock · 2,480 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F2 · derivative.exercise_date: The restricted stock units have a three year vesting schedule. 33.33% will vest on each yearly anniversary of the date of grant until fully vested.

F2 · derivative.expiration_date: The restricted stock units have a three year vesting schedule. 33.33% will vest on each yearly anniversary of the date of grant until fully vested.

SEC source: 0001127602-21-023570 · form4.xml · nonDerivative · entry 2

Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,398

SEC source: 0001127602-21-023570 · form4.xml · nonDerivative · entry 1

Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,305

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

SEC source: 0001127602-21-022506 · form4.xml · derivative · entry 3

Mercier Johanna · CIK 0001782135 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,930

Underlying: Common Stock · 7,505 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested.

F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested.